Article Text

FRI0303 Validation of eular primary sjögren’s syndrome disease activity and patient indexes
  1. R. Seror1,
  2. E. Theander2,
  3. J. Brun3,
  4. M. Ramos-Casals4,
  5. V. valim5,
  6. T. Dörner6,
  7. X. Mariette1,
  8. H. bootsma7,
  9. A. Tzioufas8,
  10. R. Solans Laqué9,
  11. T. Mandl10,
  12. J.-E. Gottenberg11,
  13. E. Hachulla12,
  14. W.-F. Ng13,
  15. S. Bombardieri14,
  16. R. Gerli15,
  17. T. sumida16,
  18. A. saraux17,
  19. M. tomsic18,
  20. R. caporali19,
  21. R. Priori20,
  22. K. Moser21,
  23. A. A. Kruize22,
  24. C. Vollenweider23,
  25. P. Ravaud24,
  26. S. Praprotnik18,
  27. H. Scofield25,
  28. G. Valesini20,
  29. C. Montecucco26,
  30. A. L. Fauchais27,
  31. C. Vitali28,
  32. S. Bowman29
  1. 1Rheumatology, Hopital Bicêtre, Le Kremlin-Bicetre, France
  2. 2Rheumatology, Hospital, Malmo, Sweden
  3. 3Rheumatology, university hospital, bergen, Norway
  4. 4Rheumatology, josef font, barcelona, Spain
  5. 5Rheumatology, University, Espirito Santo, Brazil
  6. 6Rheumatology, Charite Hospital, Berlin, Germany
  7. 7Rheumatology, UMCG, Groningen, Netherlands
  8. 8pathology, university, athens, Greece
  10. 10Rheumatology, university hospital, Malmo, Sweden
  11. 11Rheumatology, Hautepierre Hospital, strasbourg
  12. 12Internal medicine, University Hospital, Lille, France
  13. 13Rheumatology, University Hospital, Newcastle, United Kingdom
  14. 14Rheumatology, University, Pisa
  15. 15Rheumatology, Hospital, Perogia, Italy
  16. 16Rheumatology, univversity hospital, Tsukuba, Japan
  17. 17Rheumatology, hopital la cavale blanche, brest, France
  18. 18Rheumatology, Hospital, LJUBLJANA, Slovenia
  19. 19Rheumatology, POLICLINICO S MATTEO, PAVIA
  20. 20Rheumatology, POLICLINICO UMBERTO I, Roma, Italy
  21. 21Rheumatology, Medical Research Foundation, Oklahoma City, United States
  22. 22Rheumatology, Hospital, utrecht, Netherlands
  23. 23Rheumatology, University Hospital, Buenos Aires, Argentina
  24. 24Epidemiology, Hopital Hotel Dieu, Paris, France
  25. 25Rheumatology, University Hospital, Oklahoma City, United States
  26. 26Rheumatology, POLICLINICO S MATTEO, Pisa, Italy
  27. 27Rheumatology, Hospital, Limoges, France
  28. 28rheumatology, Casa di Cura, Lecco, Italy
  29. 29Rheumatology, university hospital, Birmingham, United Kingdom


Objectives To validate the EULAR scores for assessment of primary Sjögren’s Syndrome (SS): the EULAR SS Disease Activity Index (ESSDAI), the EULAR SS Patient Reported Index (ESSPRI).

Methods Prospective international validation study with 2 visits: baseline and 6 months. At each physicians completed ESSDAI, SS disease activity index (SSDAI), Sjögren’s Systemic Clinical Activity Index (SCAI) and physician global assessment (PhGA); and patients completed ESSPRI, Sicca Symptoms Inventory (SSI), Profile of Fatigue and Discomfort (PROFAD) and patient global assessment (PGA). Construct validity (using correlations with gold standard), responsiveness (using standardized response mean [SRM]) and reliability (intraclass correlation coefficient [ICC]) were evaluated and compared between each scores.

Results 395 patients (96% women, mean age 55.4 ± 13.7 years, 79% with anti-SSA and/or anti-SSB antibodies) from 15 countries have been included. At enrollment, 145 (37%) and 251 (64%) had, respectively, current or either current or past systemic manifestations. EULAR scores had higher correlation with gold standard than other scores (ESSDAI with PhGA: rho=0.59; ESSRPI with PGA: rho=0.70). Correlations between patient and systemic scores were very low (rho ranging from 0.07 to 0.29). All systemic scores had similar large responsiveness in improved patients (SRM= 0.69 to 0.82). Responsiveness of patients scores was low in patient experiencing improvement of their symptoms but was significantly higher for ESSPRI compared to SSI and PROFAD ((SRM=0.37 vs. 0.04 and 0.16; p=0.006 and 0.049 for SRM comparisons). Reliability was assessed in a subgroup of 47 and 62 patients, for systemic and patients scores, respectively. Reliability was very good for all scores (ICC=0.83 to 0.96).

Conclusions ESSDAI and ESSPRI had good construct validity. All scores were reliable. Systemic scores were sensitive to change in patients whose disease activity improves. Patient scores had a small sensitivity to change. However, ESSPRI was significantly better than SSI and PROFAD. The poor correlation between systemic and patients scores confirms that these 2 components are different and should be evaluated separately.

Disclosure of Interest: None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.